Navigation Links
Surgeons develop simpler way to cure atrial fibrillation

Physicians have an effective new option for treating atrial fibrillation, a common irregular heart rhythm that can cause stroke. Heart surgeons at Washington University School of Medicine in St. Louis have developed and tested a device that radically shortens and simplifies a complex surgical procedure that has had the best long-term cure rate for persistent atrial fibrillation.

The simplified procedure is termed Cox-maze IV, and the surgeons believe it can replace the older "cut and sew" Cox-maze III in which ten precisely placed incisions in the heart muscle created a "maze" to redirect errant electrical impulses.

"This technology has made the Cox-maze procedure much easier and quicker to perform," says Ralph Damiano Jr., M.D., the John Shoenberg Professor of Surgery and chief of cardiac surgery at the School of Medicine and a cardiac surgeon at Barnes-Jewish Hospital. "Instead of reserving the Cox-maze procedure for a select group of patients, we would urge use of this device for virtually all patients who have atrial fibrillation and are scheduled for other cardiac surgery."

The device is a clamplike instrument that heats heart tissue using radiofrequency energy. By holding areas of the heart within the jaws of the device, surgeons can create lines of ablation, or scar tissue, on the heart muscle. In the older Cox-maze III procedure, the lines of ablation were made by cutting the heart muscle, sewing the incisions back together and letting a scar form. The ablation lines redirect the abnormal electrical currents responsible for atrial fibrillation, an irregular heart rhythm in which the upper heart chambers or atria wriggle like a bag of worms.

The Cox-maze procedure was developed at the University in 1987. In their latest clinical study, reported in the February issue of the Journal of Thoracic and Cardiovascular Surgery, University surgeons showed that Cox-maze IV is just as effective as Cox-maze III for curing atrial fibri llation, yet takes one-third the time to perform.

"The older Cox-maze procedure was a very complicated operation, and very few surgeons were willing to do it," Damiano says. "So we started working on new technology and helped develop an effective ablation device that simplifies the procedure. Not only is Cox-maze IV shorter, but with the new device the procedure is also much safer because there's a much lower risk of bleeding."

Atrial fibrillation affects more than 2.2 million people in the United States and can cause fatigue, shortness of breath, exercise intolerance and palpitations. Compared to those without atrial fibrillation, those with the disorder are five times more likely to suffer from stroke and have up to a two-fold higher risk of death. For some patients, medications can control the abnormal heart rhythms and the risk of clotting associated with atrial fibrillation, but unlike the Cox-maze procedure, the drugs do not cure the disorder.

Damiano says their most recent study of Cox-maze IV is unique because the surgeons carefully matched the age, sex and cardiac conditions of a group of patients who underwent Cox-maze III in the past with patients undergoing Cox-maze IV. "This is the first documentation of the effectiveness of the ablation devices compared to the incisions of the Cox-maze III," Damiano says. "This operation is very effective, and we now use the Cox-maze IV technique exclusively."
'"/>

Source:Washington University School of Medicine


Related biology news :

1. Penn Surgeons Use Completely Robotic Surgery to Successfully Treat Prostate Cancer
2. Surgeons with video game skill appear to perform better in simulated surgery skills course
3. A much-needed shot in the arm for HIV vaccine development
4. Clam embryo study shows pollutant mixture adversely affects nerve cell development
5. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
6. Scientists develop new color-coded test for protein folding
7. Zebrafish may hold key to understanding human nerve cell development
8. First real-time view of developing neurons reveals surprises, say Stanford researchers
9. Scientists identify new model Of NK cell development
10. Influenza vaccine uses insect cells to speed development
11. Carnegie Mellon scientists develop tool that uses MRI to visualize gene expression in living animals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
Breaking Biology Technology: